Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GIST) have a wide range of mutations, but can mostly be treated with Imatinib, until eventually resistance towards this tyrosine kinase inhibitor is acquired. Early and non-invasive determination of the sensitivity of the tumor and its metastases towards Imatinib by positron emission tomography (PET) would be beneficial for therapy planning and monitoring.

Source: Nuclear Medicine and Biology - November 16, 2017 Category: Nuclear Medicine Authors: Martin Prause, Sabrina Niedermoser, Carmen W ängler, Clemens Decristoforo, Uwe Seibold, Stephanie Riester, Takahiro Taguchi, Ralf Schirrmacher, Gert Fricker, Björn Wängler Source Type: research